Decision to fund letermovir injectable formulation for prevention of Cytomegalovirus infection
What we’re doing
From 1 December 2026, letermovir Inj 20 mg per ml, 12 ml vial (brand name Prevymis) will be funded for people who have undergone an allogenic haematopoietic stem cell transplant (allo-HSCT), or who are severely immunosuppressed, and need it to prevent Cytomegalovirus (CMV) infection. The funding criteria for both the injectable and tablet formulations will also be widened to include a small number of children with inborn errors of immunity and people receiving transplants who had a different CMV status than their donor.
Why we’re proposing this
From 1 May 2026 letermovir 240 mg tablets were funded for people who had undergone an allogenic haematopoietic stem cell transplant (allo-HSCT), or who are severely immunosuppressed, and need it to prevent cytomegalovirus (CMV) infection.
Funding of letermovir 240 mg tablets was subject to a consultation dated 5 March 2026. In response to the consultation feedback Pharmac made some minor wording changes to the funding restrictions to improve clarity as part of listing these medicines from 1 May 2026.
Decision to fund letermovir tablets for prevention of cytomegalovirus infection
During the consultation, Pharmac also received feedback regarding potential benefits of further widening access criteria and funding an injectable formulation of letermovir. We were unable to resolve this feedback in time for the 1 May 2026 listing date but have since then engaged with the health sector and the supplier of letermovir to address these concerns.
Letermovir access criteria
We received feedback that the current requirement for confirmed cytomegalovirus antibodies could exclude a small number of patients, specifically children with inborn errors of immunity and people receiving transplants who had a different CMV status than their donor. Following the consultation, we engaged with our clinical advisors who told us that these people have equivalent health need to the funded group and that they would benefit substantially from receiving letermovir.
Letermovir injectable formulation
We received feedback that there were situations where having only a funded tablet formulation would cause issues with proper dosing of letermovir. These situations were mostly regarding people with side effects from the transplant process which made swallowing tablets very difficult.
They told us that Pharmac should list an alternative formulation of letermovir to address this, noting that both injectable and dissolvable granule formulations were available in other countries. At the time, our clinical advisors and consultation respondents told us that it was preferable that the potential listing of an injectable formulation of letermovir should not delay listing the tablet formulation. We funded the tablets from 1 May 2026 while continuing to work with the supplier on funding of an injectable formulation.
Who we think will be most interested
- People who have blood cancers or other conditions that may require an allogenic-haematopoietic stem cell transplant (allo-HSCT)
- Other people who are severely immunosuppressed and may be at risk of CMV infection
- Healthcare professionals involved in the care of people with blood cancers or other conditions that may require an allo-HSCT, or those who care of people who are severely immunosuppressed and may be at risk of CMV infection
- Organisations with an interest in cancer treatment such as Blood Cancer NZ or other conditions that may require people to receive an allo-HSCT
- Community and hospital pharmacies
- Hei Āhuru Mōwai
- The Cancer Society
- Pharmaceutical suppliers and wholesalers.
Detail about this decision
The following changes will occur in Section B and Part II of Section H of the Pharmaceutical Schedule.
Letermovir (Prevymis) Inj 20 mg per ml, 12 ml vial will be listed in the Herpesvirus Treatment subtherapeutic group of the Infections therapeutic group in part II of section H of the Pharmaceutical Schedule from 1 December 2026 as follows, (prices are ex-manufacturer, excl. GST):
|
Chemical |
Formulation |
Brand |
Pack size |
Price and subsidy |
|---|---|---|---|---|
|
Letermovir |
Inj 20 mg per ml, 12 ml vial |
Prevymis |
1 |
$270.00 |
The funding criteria for letermovir (Prevymis) tab 240 mg and Inj 20 mg per ml, 12 ml vial will be amended as follows from 1 December 2026. The same criteria would apply to both the tablets and the injectable formulation (additions in bold, deletions in strikethrough, only amended criteria shown):
Special Authority for Subsidy
Initial application – (CytomegalovirusMV prophylaxis - post HSCT) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:
All of the following:
- Patient has undergone an allogeneic haematopoietic stem cell transplant; and
- Patient is at high risk of cytomegalovirus disease or reactivation The patient has confirmed presence of cytomegalovirus-specific antibodies; and
- Treatment to commence within 28 days of an allogeneic haematopoietic stem cell transplant; and
- Maximum treatment duration of 100 days post-transplant.
Renewal – (CytomegalovirusMV prophylaxis – second or subsequent HSCT) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:
All of the following:
- Patient has undergone an allogeneic haematopoietic stem cell transplant; and
- Patient is at high risk of cytomegalovirus disease or reactivation The patient has confirmed presence of cytomegalovirus-specific antibodies; and
- Treatment to commence within 28 days of an allogeneic haematopoietic stem cell transplant; and
- Maximum treatment duration of 100 days post-transplant.
Similar eligibility criteria will apply in Part II of Section H of the Pharmaceutical Schedule.
Our response to what you told us
Pharmac has made the above changes in response to feedback on our original proposal to list letermovir tablets. We’re grateful for the time people took to respond to that consultation. While Pharmac has not publicly consulted a second time on letermovir a summary of the main themes raised in relation to these latest funding changes and our responses to the feedback received are available below.
|
Stakeholder group |
Theme |
Pharmac Staff Comment |
|---|---|---|
|
Hospital Antimicrobial Stewardship Committee, Stem Cell Transplant Team |
Strongly supportive but noted that there were antimicrobial stewardship concerns around the lack of an injectable formulation in the proposal. Respondents noted post-HSCT patients can have severe mucositis and are unable to swallow tablets which can make consistent dosing a challenge. Requested funding an injectable or alternative formulation suitable for these patients. |
We will be funding an injectable formulation of letermovir from 1 December 2026 to address these concerns. |
|
Hospital Transplant Team |
Supportive, however noted that dosing for paediatric stem cell transplants would be difficult with only the 240 mg tablet available. |
We will be funding an injectable formulation of letermovir from 1 December 2026 to address these concerns. |
|
Hospital Transplant Team |
Supportive, noting that the renewal criteria could be amended to include a further niche paediatric patient group and align with the transplant team's clinical practice. |
We have reviewed the proposed changes to the criteria and consulted our advisors on the Anti-infective Advisory Committee. The amendments to the funding criteria in this notification are intended to include this patient group. |
If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll-free number (9 am to 5 pm, Monday to Friday) on 0800 660 050.